3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
38
Thoracic
5
Breast
4
Gynecologic
3
Dermatologic
3
Sarcoma
2
Lymphoid
2
Head & Neck
2
Genitourinary
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Endocrine
1
CNS
1
Conditions
Glioblastoma
22
Brain Neoplasms
16
Central Nervous System Neoplasms
13
Glioma
9
Gliosarcoma
8
Neuroblastoma
7
Astrocytoma
7
Neoplasms
6
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Testicular Neoplasms
2
Sarcoma
2
Ovarian Neoplasms
2
Oligodendroglioma
2
Neoplasm Metastasis
2
Meningeal Carcinomatosis
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Interventions
Docetaxel
5
pembrolizumab
4
Radiotherapy
3
ulixertinib
2
Trastuzumab
2
Paclitaxel
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Erlotinib Hydrochloride
2
Carboplatin
2
Capecitabine
2
trastuzumab biosimilar HLX02
1
trametinib
1
tipifarnib
1
sapanisertib
1
sacituzumab govitecan
1
relatlimab
1
regorafenib
1
pertuzumab
1
palbociclib
1
osimertinib
1
oncogene protein E7, Human papillomavirus type 16
1
omipalisib
1
oblimersen
1
motexafin gadolinium
1
larotrectinib
1
ipatasertib
1
fludarabine
1
erdafitinib
1
entinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Drug Therapy
×
CNS
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled